期刊文献+

Potent Dendritic Cell Vaccine Loaded with Latent Membrane Protein 2A (LMP2A) 被引量:6

Potent Dendritic Cell Vaccine Loaded with Latent Membrane Protein 2A (LMP2A)
原文传递
导出
摘要 Epstein-Barr virus (EBV), a potential oncogenic herpesvirus, has been found to be associated with several malignancies. It's critical to elicit cellular immunity of the body to fight against EBV-associated tumor development. Using dendritic cells (DCs) loaded with latent membrane protein 2A (LMP2A) to elicit T cell response against tumor may be one of the most direct and safest immunotherapy approaches. The present study aimed to develop DCs-based cancer vaccine (DC loaded with LMP2A protein) and study its biological characteristics and immune functions. Purified LMP2A protein was extracted from a cell line L929/LMP2A stably expressing LMP2A. LMP2A could be loaded on DCs with no significant changes of the DC surface markers and cytomorphology. The percentage of DCs loaded with LMP2A was above 80%. LMP2A-loaded DCs markedly enhanced the proliferation of antigen-specific CD8^+ T and CD4^+ T cells by 3H-TdR incorporation assay. Besides, the specific cytotoxicity of the CTLs against LMP2A target cells was also significantly increased. These results indicated that DC-based vaccine loaded with virus antigen could elicit potent CTL response and provide a foundation for further study on the DC-based immunotherapy for nasopharygeal carcinoma and other EBV associated tumors. Cellular & Molecular Immunology. Epstein-Barr virus (EBV), a potential oncogenic herpesvirus, has been found to be associated with several malignancies. It's critical to elicit cellular immunity of the body to fight against EBV-associated tumor development. Using dendritic cells (DCs) loaded with latent membrane protein 2A (LMP2A) to elicit T cell response against tumor may be one of the most direct and safest immunotherapy approaches. The present study aimed to develop DCs-based cancer vaccine (DC loaded with LMP2A protein) and study its biological characteristics and immune functions. Purified LMP2A protein was extracted from a cell line L929/LMP2A stably expressing LMP2A. LMP2A could be loaded on DCs with no significant changes of the DC surface markers and cytomorphology. The percentage of DCs loaded with LMP2A was above 80%. LMP2A-loaded DCs markedly enhanced the proliferation of antigen-specific CD8^+ T and CD4^+ T cells by 3H-TdR incorporation assay. Besides, the specific cytotoxicity of the CTLs against LMP2A target cells was also significantly increased. These results indicated that DC-based vaccine loaded with virus antigen could elicit potent CTL response and provide a foundation for further study on the DC-based immunotherapy for nasopharygeal carcinoma and other EBV associated tumors. Cellular & Molecular Immunology.
出处 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2008年第5期365-372,共8页 中国免疫学杂志(英文版)
基金 the National Nature Science Foundation of China (No. 30170880 and No. 30571715) Science Committee Foundation of Jiangsu Province (No. BJ98100) Health Department Foundation of Jiangsu Province (No. H200336)
关键词 Epstein-Barr virus latent membrane protein 2A dendritic cell Epstein-Barr virus, latent membrane protein 2A, dendritic cell
  • 相关文献

参考文献10

  • 1Haque T,Wilkie GM,Jones MM, et al.Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lympho- proliferative disease: results of a phase 2 multicenter clinical trial[].Blood.2007
  • 2Savoldo B,Rooney CM,Di Stasi A, et al.Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease[].Blood.2007
  • 3Subklewe M.Dendritic cells for the induction of EBV immunity[].Cancer Research.2002
  • 4Pal C,Ganguly D,Paul K,Pal S.Dendritic cells and antigen trapping technology--a revolution in vaccine/immunotherapy strategy[].Indian Journal of Experimental Biology.2007
  • 5Loveland BE,Zhao A,White S, et al.Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma[].Clinical Cancer Research.2006
  • 6Shah SH,Soomro IN,Haroon S,Moatter T.Association of Epstein Barr virus (EBV) with nasopharyngeal carcinoma (NPC)[].Journal of the Pakistan Medical Association.2000
  • 7Pathmanathan R,Prasad U,Chandrika G,Sadler R,Flynn K,Raab-Traub N.Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx: variants of Epstein-Barr virus-infected neoplasia[].American Journal of Pathology.1995
  • 8Lee SP,Tierney RJ,Thomas WA,Brooks JM,Rickinson AB.Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy[].J Immunol.1997
  • 9Lee SP.Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy[].Seminars in Cancer Biology.2002
  • 10Leen A,Ratnayake M,Foster A, et al.Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells[].Journal of Immunotherapy.2007

同被引文献14

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部